Multiple Myeloma Patients      

FOI REFERENCE: 24039   

FOI TITLE: Multiple Myeloma Patients    

FOI DATE: 12^th April 2024  

Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which. 28 patients

Q2. Of the multiple myeloma patients over the past 6 months, how many were treated with the following:  

Belantamab Mafodotin [Blenrep] 0 patients

Bortezomib [Velcade] monotherapy or with dexamethasone 0 patients

Bortezomib, thalidomide and dexamethasone [VTD] * patients

Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd) 0 patients

Carfilzomib [Kyprolis] and dexamethasone 0 patients

Carfilzomib [Kyprolis], Lenalidomide [Revlmid] and dexamethasone * patients

Daratumumab [Darzalex] monotherapy * patients

Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd) 0 patients

Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd) 0 patients

Daratamumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone 11 patients

Elranatamab 0 patients

Idecabtagene vicleucel [Abecma] 0 patients

Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd) 0 patients

Ixazomib [Ninlaro], Lenalidomide [Revlmid] and dexamethasone (known as IRd) 0 patients

Lenalidomide [Revlmid] monotherapy 0 patients

Lenalidomide [Revlimid] and dexamethasone * patients

Pomalidomide [Imnovid] and dexamethasone 0 patients

Selinexor and dexamethasone0 patients

Talquetamab 0 patients

Teclistamab [Tecvayli] 0 patients

Any other systemic anti-cancer therapy

Zometa 10 patients

*This relates to low numbers between 1 and 5. Under section 40 (ii) of the Freedom of Information Act 2000, statistically low numbers that potentially identify personal data are required to be withheld because of the Trusts obligation to protect personal data under the Data Protection Act 2018